Bone and renal safety of initial antiviral therapy using tenofovir alafenamide fumarate or entecavir for chronic hepatitis B

Table 3 Inter-group comparison of bone and renal safety indexes at the 48-week follow-up, mean ± SD/median (Q1, Q3)

General information	TAF group (n = 45)	ETV group (n = 50)	Total (n = 95)	t value	P value
Serum calcium	2.42 ± 0.38	2.31 ± 0.15	2.36 ± 0.28	1.499	0.140
Serum phosphorus	1.06 ± 0.14	1.00 ± 0.18	1.02 ± 0.17	1.190	0.239
Serum 25-hydroxyvitamin D3	24.26 ± 9.74	22.74 ± 9.37	23.59 ± 9.51	0.555	0.581
Blood urea	4.79 (4.12, 6.30)	5.22 (4.29, 6.35)	5.03 (4.14, 6.35)	1.473	0.144
Serum creatinine	61.00 (53.00, 71.00)	62.00 (53.25, 68.75)	61.00 (53.00, 70.50)	0.182	0.856
Serum retinol-binding protein	43.5 (32.1, 50.3)	37.55 (33.38, 41.05)	38.60 (32.80, 45.85)	0.895	0.373
Serum cystatin C	0.79 (0.69, 0.91)	0.77 (0.67, 0.85)	0.78 (0.69, 0.88)	1.422	0.158
Urinary α1-microglobulin	8.14 (5.74, 9.40)	5.26 (3.25, 6.89)	6.26 (4.30, 9.00)	2.024	0.046
Urine N-acetyl-beta-D-glucosaminidase	7.85 (6.15, 9.70)	5.01 (3.56, 6.80)	6.42 (4.21, 9.33)	1.209	0.230
Urine cystatin	0.16 (0.12, 0.18)	0.14 (0.10, 0.21)	0.15 (0.11, 0.19)	0.345	0.731

TAF: Tenofovir alafenamide fumarate; ETV: Entecavir.